​

• Commercialization strategies, launch strategies, & tactical implementation support for rare disease and specialty drugs & gene therapies

• Corporate value narratives for a rare disease orphan drug manufacturers.

• Patient philosophies for a clinical stage rare and specialty companies

• Patient & caregiver engagement strategies for a clinical-stage rare disease companies.

• Creation of U.S. patient advocacy communities/platforms for rare orphan conditions

• Drug pricing strategies, market access strategies and supporting value stories for multiple rare orphan and specialty manufacturers